Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 7/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633531 | 0.85 | KMT2A (0.51) | RORCPDE4BPDE4DKMT2ACA5A | |
| SCHEMBL29633602 | 0.82 | HSD17B10 (0.45) | LMNARORCPDE4BPDE4DKMT2A | |
| SCHEMBL14003536 | 0.76 | PDE4B (0.61) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL21266950 | 0.76 | SERPINE1 (0.50) | LMNAPDE4BPDE4DMAPK14KMT2A | |
| SCHEMBL17321002 | 0.75 | KAT6A (0.48) | LMNAKMT2ACA5AALDH1A1 | |
| SCHEMBL17895369 | 0.75 | PDE4B (0.50) | PDE4BPDE4DMAPK14KMT2APDE4A | |
| SCHEMBL8237277 | 0.75 | CREBBP (0.45) | LMNARORCPDE4BPDE4DMAPK14 | |
| SCHEMBL12327904 | 0.74 | LMNA (0.69) | LMNAKMT2ACA5AUSP2ALDH1A1 | |
| SCHEMBL26030947 | 0.74 | RORC (0.43) | RORCPDE4BPDE4DMAPK14KMT2A | |
| SCHEMBL22946087 | 0.73 | CREBBP (0.54) | LMNAKMT2AUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021020429-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | 大正製薬株式会社 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | LMNA 2200/4885RORC 2136/4885PDE4B 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.